Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 27, Issue 4 SUPPL. 55, 2009, Pages

  Haibel, Hildrun ^a   Specker, Christof ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Eye Hospital   (Germany)

Author keywords

Ankylosing spondylitis; Comparison; DMARD; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; THALIDOMIDE;

ANKYLOSING SPONDYLITIS; BACKACHE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORNING STIFFNESS; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UVEITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG COMBINATIONS; HUMANS; SPONDYLITIS, ANKYLOSING; SULFASALAZINE;

EID: 71249103013     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. BREBAN M, RAVAUD P, CLAUDEPIERRE P et al.: No Superiority of infliximab (INF) + methotrexate (MTX) over INF Alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective study. Arthritis Rheum 2005; 52 (Suppl.): S214.
2. HEIBERG MS, NORDVAG BY, MIKKELSEN K et al.: The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52: 2506-2512
3. WARD MM, KUZIS S: Medication toxicity among patients with ankylosing spondylitis. Arthritis Rheum 2002; 47: 234-241 (Pubitemid 34627689)
4. SUAREZ-ALMAZOR ME, BELSECK E, SHEA B, WELLS G, TUGWELL P: Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000: CD000958.
5. HAAGSMA CJ, VAN RIEL PL, DE JONG AJ, VAN DE PUTTE LB: Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-1088 (Pubitemid 27488688)
6. DOUGADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-225
7. CAPELL HA, MADHOK R, PORTER DR et al.: Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66: 235-241
8. MAETZEL A, WONG A, STRAND V, TUGWELL P, WELLS G, BOMBARDIER C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39: 975-981
9. DONAHUE KE, GARTLEHNER G, JONAS DE et al.: Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-134
10. CHEN J, LIU C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005: CD004800.
11. NISSILA M, LEHTINEN K, LEIRISALO-REPO M, LUUKKAINEN R, MUTRU O, YLI-KERTTULA U: Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988; 31: 1111-1116
12. DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618-627
13. CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42: 2325-2329
14. BRAUN J, ZOCHLING J, BARALIAKOS X et al.: Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65: 1147-1153
15. LEHTINEN A, LEIRISALO-REPO M, TAAVIT-SAINEN M: Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-up. Clin Exp Rheumatol 1995; 13: 733-736
16. BENITEZ-DEL-CASTILLO JM, GARCIA-SANCHEZ J, IRADIER T, BANARES A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000; 14 (Pt 3A): 340-343
17. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
18. SUAREZ-ALMAZOR ME, BELSECK E, SHEA B, WELLS G, TUGWELL P: Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000: CD000957.
19. WEINBLATT ME, KAPLAN H, GERMAIN BF et al.: Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37: 1492-1498
20. WEINBLATT ME, WEISSMAN BN, HOLDSWORTH DE et al.: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992; 35: 129-137
21. KREMER J: Use of methotrexate in the treatment of rheumatoid arthritis. UpToDate 2009; 17.1:.
22. RICH E, MORELAND LW, ALARCON GS: Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 1999; 26: 259-261 (Pubitemid 29066725)
23. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177 (Pubitemid 34304256)
24. VISSER K, VAN DER HEIJDE D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2008.
25. LAMBERT CM, SANDHU S, LOCHHEAD A, HURST NP, MCRORIE E, DHILLON V: Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 2004; 50: 364-371
26. BRAUN J, KASTNER P, FLAXENBERG P et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
27. BRAUN J, SIEPER J: Ankylosing spondylitis Lancet 2007; 369: 1379-1390
28. CHEN J, LIU C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004: CD004524.
29. HAIBEL H, BRANDT HC, SONG IH et al.: No efficacy of subcutaneous methotrexate in active ankylosing spondylitis - a 16 weeks open label trial. Ann Rheum Dis 2006.
30. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-66.
31. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-2550
32. EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-665
33. OSIRI M, SHEA B, ROBINSON V et al.: Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003: CDO02047.
34. HAIBEL H, RUDWALEIT M, BRAUN J, SIEPER J: Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 124-126 (Pubitemid 40075288)
35. VAN DENDEREN JC, VAN DER PAARDT M, NURMOHAMED MT, DE RYCK YM, DIJKMANS BA, VAN DER HORST-BRUINSMA IE: Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 1761-1764
36. BREBAN M, GOMBERT B, AMOR B, DOUGADOS M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999; 42: 580-581
37. HUANG F, GU J, ZHAO W, ZHU J, ZHANG J, YU DT: One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 47: 249-254
38. WEI JC, CHAN TW, LIN HS, HUANG F, CHOU CT: Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 2003; 30: 2627-2631
39. MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766-73.
40. HAIBEL H, BRANDT J, RUDWALEIT M, SOERENSEN H, SIEPER J, BRAUN J: Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 2003; 42: 1018-1020 (Pubitemid 37220983)
41. GROVER R, SHANKAR S, ANEJA R, MARWAHA V, GUPTA R, KUMAR A: Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 2006; 65: 688-689
42. SMOLEN JS, ALETAHA D, KEYSTONE E: Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum 2005; 52: 2975-2983
43. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-733
44. SCHOELS M, KAPRAL T, STAMM T, SMOLEN JS, ALETAHA D: Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis 2007; 66: 1059-1065
45. MOTTONEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FINRACo trial group. Lancet 1999; 353: 1568-73.
46. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-318
47. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-3390
48. KLARENBEEK NB, ALLAART CF, KERSTENS PJ, HUIZINGA TW, DIJKMANS BA: The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 291-298
49. RANTALAIHO V, KORPELA M, HANNONEN P et al.: The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60: 1222-1231